C07F 9/6527
Having nitrogen and oxygen atoms as the only ring hetero atoms
Official title: having nitrogen and oxygen atoms as the only ring hetero atoms
C07F9/6527 (Having nitrogen and oxygen atoms as the only ring hetero atoms) appears on 584 US grants and 399 published applications in this corpus.
Search patents in C07F- Granted patents
- 584
- Published applications
- 399
- Assignees
- 317
- Inventors
- 1,501
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 13 | 0 |
| 1977 | 16 | 0 |
| 1978 | 18 | 0 |
| 1979 | 12 | 0 |
| 1980 | 19 | 0 |
| 1981 | 16 | 0 |
| 1982 | 5 | 0 |
| 1983 | 5 | 0 |
| 1984 | 6 | 0 |
| 1985 | 16 | 0 |
| 1986 | 10 | 0 |
| 1987 | 8 | 0 |
| 1988 | 8 | 0 |
| 1989 | 8 | 0 |
| 1990 | 10 | 0 |
| 1991 | 11 | 0 |
| 1992 | 5 | 0 |
| 1993 | 12 | 0 |
| 1994 | 11 | 0 |
| 1995 | 12 | 0 |
| 1996 | 10 | 0 |
| 1997 | 16 | 0 |
| 1998 | 12 | 0 |
| 1999 | 12 | 0 |
| 2000 | 4 | 0 |
| 2001 | 9 | 1 |
| 2002 | 15 | 17 |
| 2003 | 14 | 6 |
| 2004 | 5 | 19 |
| 2005 | 10 | 27 |
| 2006 | 14 | 33 |
| 2007 | 10 | 10 |
| 2008 | 19 | 20 |
| 2009 | 12 | 17 |
| 2010 | 12 | 16 |
| 2011 | 7 | 15 |
| 2012 | 16 | 21 |
| 2013 | 17 | 12 |
| 2014 | 22 | 27 |
| 2015 | 17 | 21 |
| 2016 | 21 | 20 |
| 2017 | 11 | 25 |
| 2018 | 15 | 12 |
| 2019 | 17 | 12 |
| 2020 | 11 | 17 |
| 2021 | 8 | 10 |
| 2022 | 8 | 7 |
| 2023 | 9 | 11 |
| 2024 | 3 | 8 |
| 2025 | 6 | 5 |
| 2026 | 1 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer10 Mar 2026US 12,570,620 B2Dana-Farber Cancer Institute, Inc.
- Reagents and their use for modular enantiodivergent synthesis of C—P bonds9 Dec 2025US 12,492,217 B2Bristol-Myers Squibb Company
- Oxazolidinone compounds and methods of use thereof as antibacterial agents22 Jul 2025US 12,365,656 B2Merck Sharp & Dohme Corp.
- Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof22 Jul 2025US 12,365,673 B2Haisco Pharmaceuticals Pte. Ltd.
- Phosphorodiamidate morpholino oligomers13 May 2025US 12,297,219 B2Sarepta Therapeutics, Inc.
- Nucleotide substitute having enhanced stability3 Sep 2026US 2026/0258409 A1Rona Bioscience, Limited
- Azetidinyl benzoxazole compounds and their use as mer and axl inhibitors13 Aug 2026US 2026/0232658 A1Dong-A St Co., Ltd.
- Phosphine oxide-based photoinitiators23 Jul 2026US 2026/0209256 A1Arkema France
- Morpholine-based organophosphine ligand, preparation method therefor and application thereof28 May 2026US 2026/0146056 A1Henan academy of sciences
- Reagents and their use for modular enantiodivergent synthesis of c-p bonds21 May 2026US 2026/0138999 A1Bristol-Myers Squibb Company
Most cited
By later US patents
- Electrochromic device368US 6,870,657 B1University College Dublin · 2005
- Cationic phospholipids for transfection153US 5,780,053 ANorthwestern University · 1998
- Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties148US 5,344,930 AAlliance Pharmaceutical Corp. · 1994
- Ligands for metals and improved metal-catalyzed processes based thereon143US 6,307,087 B1Massachusetts Institute of Technology · 2001
- Cationic phospholipids for transfection119US 5,855,910 ANorthwestern University · 1999